Cargando…

Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis

OBJECTIVES: To evaluate the effects of atomoxetine on complex attention and other neurocognitive domains in idiopathic Parkinson's disease (PD). METHODS: Interventional trials reporting changes in complex attention and other neurocognitive functions (Diagnostic and Statistical Manual of Mental...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghosh, Abhinaba, Das, Saibal, Behera, Sapan Kumar, Ramakrishnan, Kirubakaran, Selvarajan, Sandhiya, Kandasamy, Preeti, Nair, N Sreekumaran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049416/ https://www.ncbi.nlm.nih.gov/pubmed/32211146 http://dx.doi.org/10.1155/2020/4853590

Ejemplares similares

Hepatitis B Vaccine and Immunoglobulin: Key Concepts
por: Das, Saibal, et al.
Publicado: (2019)

Indian Council of Medical Research's National Ethical Guidelines for biomedical and health research involving human participants: The way forward from 2006 to 2017
por: Behera, Sapan Kumar, et al.
Publicado: (2019)

Are drug-drug interactions a real clinical concern?
por: Das, Saibal, et al.
Publicado: (2019)

Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
por: Behera, Sapan K., et al.
Publicado: (2019)

Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023)

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
por: Hammerness, Paul, et al.
Publicado: (2009)

Atomoxetine for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children with ADHD and dyslexia
por: Sumner, Calvin R, et al.
Publicado: (2009)

Efficacy and Safety of Atomoxetine in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder
por: Kohn, Michael R., et al.
Publicado: (2012)

Effect of Atomoxetine on Hyperactivity in an Animal Model of Attention-Deficit/Hyperactivity Disorder (ADHD)
por: Moon, Su Jin, et al.
Publicado: (2014)

Real‐World Dosing Patterns of Atomoxetine in Adults with Attention‐Deficit/Hyperactivity Disorder
por: Kabul, Samaneh, et al.
Publicado: (2015)

Atomoxetine-Associated Eyebrow Alopecia in a Girl With Attention-Deficit/Hyperactivity Disorder
por: Zhang, Ying, et al.
Publicado: (2021)

Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
por: Nagai, Tsutomu, et al.
Publicado: (2022)

Advanced Test of Attention in Children with Attention-Deficit/Hyperactivity Disorder in Japan for Evaluation of Methylphenidate and Atomoxetine Effects
por: Fujioka, Toru, et al.
Publicado: (2016)

Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder
por: Garg, Jasmin, et al.
Publicado: (2015)

Atomoxetine Induced Hypomania in a Patient with Bipolar Disorder and Adult Attention Deficit Hyperactivity Disorder
por: Kumar, Vijaya, et al.
Publicado: (2017)

Systematic Review of Suicidal Behaviors Related to Methylphenidate and Atomoxetine in Patients With Attention Deficit Hyperactivity Disorder
por: Kim, Jae Heon, et al.
Publicado: (2023)

Efficacy of atomoxetine in adult attention-Deficit/Hyperactivity Disorder: a drug-placebo response curve analysis
por: Faraone, Stephen V, et al.
Publicado: (2005)

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder
por: Upadhyaya, Himanshu P., et al.
Publicado: (2013)

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
por: Joseph, Alain, et al.
Publicado: (2016)

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder
por: Clemow, David B., et al.
Publicado: (2016)

Clinical effects of repetitive transcranial magnetic stimulation combined with atomoxetine in the treatment of attention-deficit hyperactivity disorder
por: Cao, Pengfei, et al.
Publicado: (2018)

Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study
por: Ruppert, Katrin, et al.
Publicado: (2022)

Targeting impulsivity in Parkinson’s disease using atomoxetine
por: Kehagia, Angie A., et al.
Publicado: (2014)

Improving Response Inhibition in Parkinson’s Disease with Atomoxetine
por: Ye, Zheng, et al.
Publicado: (2015)

Drug information center as referral service in a South Indian tertiary care hospital
por: Behera, Sapan Kumar, et al.
Publicado: (2017)

A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder
por: Carlson, Gabrielle A, et al.
Publicado: (2007)

A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain
por: Hong, Jihyung, et al.
Publicado: (2009)

A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
por: Clemow, David B, et al.
Publicado: (2017)

Differential therapeutic effects of atomoxetine and methylphenidate in childhood attention deficit/hyperactivity disorder as measured by near-infrared spectroscopy
por: Nakanishi, Yoko, et al.
Publicado: (2017)

Clinical and Neuropsychological Factors Associated with Treatment Response and Adverse Events of Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder
por: Park, Kee Jeong, et al.
Publicado: (2019)

A case report: ‘happy heart’ syndrome in a patient treated with atomoxetine for attention deficit hyperactivity disorder
por: Athanassopoulos, Petros, et al.
Publicado: (2019)

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease
por: Borchert, Robin J, et al.
Publicado: (2016)

Atomoxetine restores the response inhibition network in Parkinson’s disease
por: Rae, Charlotte L., et al.
Publicado: (2016)

Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials
por: Wehmeier, Peter M, et al.
Publicado: (2010)

Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis
por: Hanwella, Raveen, et al.
Publicado: (2011)

Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Systematic Review of Review Papers 2009–2011. An Update for Clinicians
por: Bushe, Chris J., et al.
Publicado: (2011)

Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials
por: Asherson, Philip, et al.
Publicado: (2014)

Effect of Atomoxetine on the Cognitive Functions in Treatment of Attention Deficit Hyperactivity Disorder in Children with Congenital Hypothyroidism: A Pilot Study
por: Yang, Rongwang, et al.
Publicado: (2015)

Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine
por: Imagawa, Hideyuki, et al.
Publicado: (2018)

Effects of Atomoxetine on Height and Weight in Korean Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review
por: Kweon, Kukju, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lhp8oafijij8abe2a6gk1s99ki